Passage Bio, Inc. (PASG) – What Are Analysts Saying About This Stock?

Shares of Passage Bio, Inc. (NASDAQ:PASG – Get Free Report) have earned an average recommendation of “Hold” from the nine brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $13.25.

Several equities research analysts have recently issued reports on the company. Wall Street Zen cut Passage Bio from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings cut shares of Passage Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th.

Get Passage Bio alerts:

View Our Latest Research Report on Passage Bio

Institutional Investors Weigh In On Passage Bio

An institutional investor recently bought a new position in Passage Bio stock. Eversept Partners LP acquired a new position in Passage Bio, Inc. (NASDAQ:PASG – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 126,230 shares of the company’s stock, valued at approximately $1,490,000. Eversept Partners LP owned 3.97% of Passage Bio at the end of the most recent reporting period. Institutional investors own 53.48% of the company’s stock.

Passage Bio Stock Performance

Shares of PASG stock opened at $4.55 on Tuesday. The stock has a fifty day simple moving average of $4.56 and a two-hundred day simple moving average of $5.44. The firm has a market capitalization of $14.65 million, a PE ratio of -0.40 and a beta of 1.40. Passage Bio has a 52-week low of $3.29 and a 52-week high of $20.00.

Passage Bio (NASDAQ:PASG – Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($2.44) EPS for the quarter, hitting analysts’ consensus estimates of ($2.44). On average, sell-side analysts forecast that Passage Bio will post -9.19 EPS for the current fiscal year.

Passage Bio Company Profile

(Get Free Report)

Passage Bio, Inc is a clinical-stage biotechnology company developing genetic medicines for severe diseases of the central nervous system. The company focuses on conditions with significant unmet medical needs and uses adeno-associated virus (AAV) gene-delivery technologies to develop potential one-time treatments intended to address the underlying causes of disease.

Its research and development programs have included investigational therapies for rare neurological and neurodegenerative disorders, including GM1 gangliosidosis, Krabbe disease and frontotemporal dementia associated with progranulin gene mutations.

Read More

• Five stocks we like better than Passage Bio
• The Pentagon’s $350 Million Quantum Push: Why IonQ Could Benefit More Than D-Wave
• Delta’s Guidance Cut Could Spell Trouble for the Airline Industry
• Salesforce Just Got a Rare Double Upgrade—What Changed?
• OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors

Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.